Publications by authors named "Alexa J Luboff"
Ann Pharmacother
December 2024
Article Synopsis
- The objective of this review is to assess capivasertib's pharmacology, efficacy, and safety for treating advanced breast cancer patients who are hormone receptor-positive and HER2-negative, particularly those with specific genetic alterations like PIK3CA and AKT1.
- Capivasertib is a pioneering drug that inhibits key AKT isoforms in the PI3K/AKT/mTOR pathway and has shown improved progression-free survival in trials, especially when combined with fulvestrant, compared to a placebo.
- This drug offers a promising option for patients who have not responded to previous treatments, demonstrating manageable side effects and potential for integration into standard care practices for advanced breast cancer.
